FDA RWE Guidance & CMS Star Ratings

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics hit at the intersection of regulatory evolution and real-world evidence generation. That's where the field is right now.

MarcusSame here. We're looking at FDA's draft guidance on real-world evidence for accelerated approvals — this reshapes how we support novel mechanisms. Then CMS's proposed changes to Medicare Advantage Star Ratings — that could fundamentally shift provider incentives. Plus, NICE's updated framework for digital therapeutics in chronic conditions — signaling broader acceptance. And the EU HTA Regulation's first wave of joint clinical assessments for oncology drugs — finally operational.

SaraThat second one is particularly interesting to me — the Star Ratings methodology shift creates new budget impact considerations for manufacturers. How we demonstrate value in those metrics will need recalibration.

MarcusExactly. Let's get into it.

MarcusStarting with the FDA draft guidance on RWE for accelerated approvals. This is significant because it formalizes pathways for supplementing traditional endpoints with real-world data, especially in areas like neurodegenerative diseases where traditional endpoints are challenging. The guidance emphasizes methodological rigor for RWE supporting accelerated approvals.

SaraThat's one read. But what strikes me is the tension between accelerated approval timelines and the need for robust RWE. Payers will scrutinize the durability of evidence generated post-approval. The guidance doesn't fully address how RWE will be used in confirmatory trials, which is where the real access battles happen.

MarcusFair point. The guidance does stress the need for pre-specified RWE plans, but it leaves room for interpretation on how those plans interact with confirmatory studies. I wonder if that's the full picture though — the FDA is essentially creating a dual-track system where RWE can both support initial approval and later confirm value. That's unprecedented.

SaraThe part that gives me pause is the potential for inconsistent application. If one RWE study supports an accelerated approval but another doesn't meet the same threshold for confirmatory evidence, we could see divergent outcomes across indications. That creates uncertainty for both manufacturers and payers.

MarcusThat connects to something I keep coming back to — the resource implications. Generating high-quality RWE is resource-intensive. This guidance implicitly shifts some of that burden to manufacturers during development. The question is whether the trade-off between speed and evidence quality is worth it for truly innovative therapies.

SaraRight, and from the payer side, we need more clarity on how RWE will be integrated into coverage decisions. The guidance doesn't address how CMS or private payers will weight RWE versus traditional endpoints. That's a critical gap in the ecosystem.

MarcusAbsolutely. The guidance is a step forward, but it creates more questions than answers about the long-term evidence framework. Let's move to the Star Ratings changes.

SaraCMS proposed changes to Medicare Advantage Star Ratings for 2027. This matters because Star Ratings directly impact payments to Medicare Advantage plans, and they're increasingly focusing on patient-reported outcomes and social determinants of health. The new weights on quality metrics could significantly alter how plans prioritize therapies.

MarcusThat's correct. The proposed shift toward more granular patient experience metrics and social risk adjustment could create opportunities for therapies that improve quality of life beyond clinical endpoints. But I'd push back slightly on the immediate commercial implications — these changes are still in proposed form, and the implementation timeline remains uncertain.

SaraThat's one read, but the signal is clear. CMS is moving toward value-based metrics that capture holistic patient outcomes. For manufacturers, this means developing evidence strategies that demonstrate impact on these new domains. The budget impact question here is substantial — how do we value improvements in patient experience versus traditional clinical measures?

MarcusWhat's striking here is how this intersects with the FDA's RWE guidance. If CMS starts using real-world data to assess Star Ratings, and FDA is using RWE for approvals, we could see a convergence in evidence requirements. But the methodological differences between regulatory and coverage evidence remain a challenge.

SaraExactly. The Star Ratings changes also create a new layer of evidence generation post-launch. Manufacturers may need to conduct post-marketing studies specifically to support these metrics, adding to the overall evidence burden. The opportunity cost of that investment is significant.

MarcusThat's fair, though I think payers would see it differently — these metrics could actually help demonstrate value for therapies that improve daily functioning but don't show traditional efficacy benefits. The tension is between granularity and administrative feasibility. CMS is trying to capture nuance, but will the data support it?

SaraThe nuance is exactly where the field needs to focus. We've moved beyond simple efficacy metrics to understanding how treatments impact patients' lives. That's progress, even if it creates complexity. Let's discuss NICE's digital health framework next.

MarcusNICE has published an updated framework for digital therapeutics in chronic conditions. This is significant because it addresses the unique evidence challenges of digital health interventions, including endpoints and cost-effectiveness. The framework acknowledges the dynamic nature of these technologies.

SaraThat's one read, but I'm struck by the practical implementation hurdles. The framework emphasizes real-world evidence generation, but how do we standardize data collection across different digital platforms? The heterogeneity in digital therapeutics makes traditional HTA approaches difficult to apply.

MarcusWhat strikes me is the recognition of iterative development. NICE is allowing for evidence generation post-initial assessment, which acknowledges that digital health evolves rapidly. That's a pragmatic shift from traditional static technology appraisals. But I wonder if that's the full picture — how do we ensure this doesn't become a moving target for manufacturers?

SaraThe part that gives me pause is the cost-effectiveness assessment. Digital therapeutics often have lower development costs but ongoing maintenance expenses. The framework doesn't fully address how to model long-term value versus upfront costs. That creates uncertainty for both companies and payers.

MarcusThat connects to something I keep coming back to — the patient perspective. These interventions can improve access in underserved areas, but only if the evidence framework supports their adoption. The framework's focus on health inequalities is welcome, but the methodological rigor still needs work.

SaraRight, and from the payer side, we need more clarity on how to incorporate digital health into existing pathways. The framework is a step forward, but it doesn't resolve the tension between innovation and standardization. How do we maintain flexibility without compromising evidence quality?

MarcusThe framework signals NICE's willingness to adapt, but the real test will be in how these assessments translate to coverage decisions. Let's finish with the EU oncology JCAs.

SaraThe EU HTA Regulation has launched its first wave of joint clinical assessments for oncology drugs. This is a milestone because it's the first operational application of the EU HTA system, bringing together EMA and national HTA bodies. The focus on oncology makes sense given the high unmet need.

MarcusThat's correct. The JCA process aims to reduce duplication across member states, but the initial oncology focus creates methodological challenges. Oncology trials often use surrogate endpoints, and the JCA will need to address how to assess value in these settings. The first reports will set precedents for other disease areas.

SaraI'd frame it slightly differently — the real significance is the potential for harmonization. If the JCA can establish consistent value assessments across countries, it could streamline market access. But the question is whether national HTA bodies will adapt their own processes to align with the JCA outputs.

MarcusWhat strikes me is the timing. With the EU Critical Medicines Act accelerating timelines, the JCA process is being asked to deliver faster assessments. That creates tension with the need for thorough evidence evaluation. How do we balance speed with methodological rigor in oncology?

SaraThe part that gives me pause is the budget impact implications. If multiple countries adopt JCA recommendations, it could create sudden demand spikes for oncology drugs. The process doesn't fully address how to manage system-wide budget impact when multiple countries make coverage decisions simultaneously.

MarcusThat's fair, though I think the industry would see it as a positive step toward reducing fragmentation. The JCA could actually help manufacturers demonstrate value more efficiently across Europe. But the challenge will be maintaining scientific independence while aligning national interests.

SaraExactly. The first wave will test whether the JCA can deliver on its promise of efficiency without compromising evidence quality. That's the critical test for the entire EU HTA system.

SaraA lot to think about today. I'll be watching how CMS's Star Ratings implementation plays out — particularly the impact on patient-reported outcomes metrics and how manufacturers adapt their evidence strategies.

MarcusSame — and for me the thread running through today is the evolving relationship between regulatory approvals and coverage evidence. Whether it's FDA's RWE guidance, CMS's new metrics, or the EU's JCA process, we're seeing a shift toward more flexible, real-world evidence frameworks. That's worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.